Please assess the completion status of the following clinical trial:

Trial Title: Impact of Interleukin 28B (rs12979860) Genotype on Virological Responses Chronic Hepatitis C Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with diagnosis of chronic hepatitis C genotype 2 or 3~Exclusion Criteria:~* Patients with hepatitis genotype I and IV

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- chronic hepatitis C genotype 2 or 3 (Type: EXPERIMENTAL): In all patients Pegylated Interferon α2 (pegIFN) plus Ribavirin were given in standard doses. Peg-INF was given in a dose of 180 μg/week and ribavirin 1200 mg/day to every patient for the period of 24 weeks for HCV genotype 2 \& 3

Based on this trial design, predict the completion outcome and termination type (if applicable).